Entrada announces FDA removal of clinical hold on ENTR-601-44
FDA Approval for Clinical Study: Entrada Therapeutics has received FDA authorization to lift the clinical hold on ENTR-601-44 and initiate the ELEVATE-44-102 Phase 1b study, aimed at treating Duchenne muscular dystrophy in adults with specific DMD gene mutations.
Study Details and Future Plans: The ELEVATE-44-102 study will evaluate the safety and tolerability of ENTR-601-44 in approximately 32 patients, with dosing planned every six weeks. Enrollment is expected to begin in the first half of 2026, potentially leading into an open-label extension study.
Trade with 70% Backtested Accuracy
Analyst Views on TRDA
About TRDA
About the author
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be live-streamed on Entrada's Investor Relations website and will be archived for 30 days post-event, ensuring that investors who cannot attend in real-time can access key information, thereby enhancing the company's transparency.
- Company Background: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing Endosomal Escape Vehicle (EEV™) therapeutics that enable efficient delivery of treatments, aiming to improve therapeutic indices and provide potential solutions for neuromuscular and ocular diseases, highlighting its strategic positioning in innovative drug development.
- R&D Project Progress: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and is collaborating on a clinical-stage program, VX-670, for myotonic dystrophy type 1, indicating its deep commitment and market potential in specific disease areas.
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The presentation will be available via live webcast on Entrada's Investor Relations website, with a replay accessible for 30 days post-event, aimed at increasing engagement and transparency with potential investors.
- Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuromuscular and ocular diseases, showcasing its cutting-edge position in the biopharmaceutical sector.
- Product Development: The company is advancing a robust portfolio of RNA and protein-based programs, particularly targeting treatments for Duchenne muscular dystrophy, indicating its potential in addressing challenging diseases.
Entrada Therapeutics Grants 40,650 RSUs and Options to New Employees
- Employee Incentive Program: Entrada Therapeutics granted 40,650 restricted stock units and options for 38,850 shares to five newly hired non-executive employees under its 2025 Inducement Equity Plan, aimed at attracting talent and enhancing team stability.
- Option Exercise Price: The options have an exercise price of $9.91 per share, matching the closing price of the company's common stock on December 1, 2025, ensuring that employee interests are closely aligned with the company's stock performance.
- Vesting Schedule: Each employee's options will vest one-fourth on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in thirty-six equal monthly installments, which helps to improve long-term employee retention.
- Strategic Company Development: By implementing the Inducement Equity Plan, Entrada not only attracts key talent but also enhances its competitiveness in the biopharmaceutical industry, facilitating progress in its therapeutic programs targeting neuromuscular and ocular diseases.
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?
5AM Venture Management's Exit: The firm completely liquidated its position in Viking Therapeutics, selling 189,593 shares for an estimated net position change of $5.02 million, reducing its stake from 1.9% to zero as of Q3 2025.
Market Performance: As of November 18, 2025, Viking Therapeutics shares were priced at $38.00, down 5.6% year-to-date, underperforming the S&P 500 by 18.7 percentage points.
Investment Perspective: The sale is viewed as a rebalancing strategy rather than a lack of confidence in Viking's drug development, emphasizing the long-term nature of investing in clinical-stage biopharmaceuticals.
Investor Insights: The article highlights that individual investors in development-stage biotech must be patient and resilient, as stock movements are primarily driven by clinical data rather than trading activity.
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note
5AM Venture Management's Exit: The fund sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated $13.33 million, which previously represented 5.12% of its assets.
Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and significantly underperforming the S&P 500.
Risk Management Strategy: The decision to exit the investment is seen as a move to reduce risk amid the stock's poor performance, indicating a shift towards more stable investments.
Clinical Development Focus: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial outcomes and milestones.
3 'Strong Buy' Stocks to Consider Now with Potential Upside Exceeding 125%, Analysts Say (10/24/2025)
Top Stock Picks: Three stocks have been identified as Strong Buys by top Wall Street analysts, each with significant upside potential based on recent ratings.
Entrada Therapeutics (TRDA): This biotech company has a Buy rating from all three top analysts covering it, with a projected upside of approximately 212.5%.
Exodus Movement, Inc. (EXOD): A software company with a Buy rating from all six top analysts, it has a price target of $50 per share, indicating an upside of about 127.8%.
Nurix Therapeutics (NRIX): This biotech firm has a majority Buy rating from top analysts, with a revised price target of $21 per share, suggesting an upside of around 128%.
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be live-streamed on Entrada's Investor Relations website and will be archived for 30 days post-event, ensuring that investors who cannot attend in real-time can access key information, thereby enhancing the company's transparency.
- Company Background: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing Endosomal Escape Vehicle (EEV™) therapeutics that enable efficient delivery of treatments, aiming to improve therapeutic indices and provide potential solutions for neuromuscular and ocular diseases, highlighting its strategic positioning in innovative drug development.
- R&D Project Progress: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and is collaborating on a clinical-stage program, VX-670, for myotonic dystrophy type 1, indicating its deep commitment and market potential in specific disease areas.
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The presentation will be available via live webcast on Entrada's Investor Relations website, with a replay accessible for 30 days post-event, aimed at increasing engagement and transparency with potential investors.
- Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuromuscular and ocular diseases, showcasing its cutting-edge position in the biopharmaceutical sector.
- Product Development: The company is advancing a robust portfolio of RNA and protein-based programs, particularly targeting treatments for Duchenne muscular dystrophy, indicating its potential in addressing challenging diseases.
Entrada Therapeutics Grants 40,650 RSUs and Options to New Employees
- Employee Incentive Program: Entrada Therapeutics granted 40,650 restricted stock units and options for 38,850 shares to five newly hired non-executive employees under its 2025 Inducement Equity Plan, aimed at attracting talent and enhancing team stability.
- Option Exercise Price: The options have an exercise price of $9.91 per share, matching the closing price of the company's common stock on December 1, 2025, ensuring that employee interests are closely aligned with the company's stock performance.
- Vesting Schedule: Each employee's options will vest one-fourth on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in thirty-six equal monthly installments, which helps to improve long-term employee retention.
- Strategic Company Development: By implementing the Inducement Equity Plan, Entrada not only attracts key talent but also enhances its competitiveness in the biopharmaceutical industry, facilitating progress in its therapeutic programs targeting neuromuscular and ocular diseases.
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?
5AM Venture Management's Exit: The firm completely liquidated its position in Viking Therapeutics, selling 189,593 shares for an estimated net position change of $5.02 million, reducing its stake from 1.9% to zero as of Q3 2025.
Market Performance: As of November 18, 2025, Viking Therapeutics shares were priced at $38.00, down 5.6% year-to-date, underperforming the S&P 500 by 18.7 percentage points.
Investment Perspective: The sale is viewed as a rebalancing strategy rather than a lack of confidence in Viking's drug development, emphasizing the long-term nature of investing in clinical-stage biopharmaceuticals.
Investor Insights: The article highlights that individual investors in development-stage biotech must be patient and resilient, as stock movements are primarily driven by clinical data rather than trading activity.
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note
5AM Venture Management's Exit: The fund sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated $13.33 million, which previously represented 5.12% of its assets.
Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and significantly underperforming the S&P 500.
Risk Management Strategy: The decision to exit the investment is seen as a move to reduce risk amid the stock's poor performance, indicating a shift towards more stable investments.
Clinical Development Focus: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial outcomes and milestones.
3 'Strong Buy' Stocks to Consider Now with Potential Upside Exceeding 125%, Analysts Say (10/24/2025)
Top Stock Picks: Three stocks have been identified as Strong Buys by top Wall Street analysts, each with significant upside potential based on recent ratings.
Entrada Therapeutics (TRDA): This biotech company has a Buy rating from all three top analysts covering it, with a projected upside of approximately 212.5%.
Exodus Movement, Inc. (EXOD): A software company with a Buy rating from all six top analysts, it has a price target of $50 per share, indicating an upside of about 127.8%.
Nurix Therapeutics (NRIX): This biotech firm has a majority Buy rating from top analysts, with a revised price target of $21 per share, suggesting an upside of around 128%.
